{"pmid":32412511,"title":"High-flow cannulas will be required with current COVID-19 crisis, not only mechanical ventilators.","text":["High-flow cannulas will be required with current COVID-19 crisis, not only mechanical ventilators.","COVID-19 is characterized by acute respiratory distress syndrome progression, which ranges from mild to severe. A percentage of critically ill patients will require endotracheal intubation and mechanical ventilation; therefore, Mexican engineers from different places have had the initiative of creating mechanical ventilators. Although artificial ventilator is one of the last resources for the most severely ill patients, there are patients who are on the verge of not meeting the criteria for intubation; if they are directly intubated, the opportunity for them to overcome the severe phase with high concentration supplemental oxygen would be be missed. Intubation per se induces lung damage, increases the risk of superinfection, and the number of days of ICU stay. Furthermore, non-selective use of artificial ventilators decreases the opportunity for patients who require a ventilator to survive and increases institutional care costs of both human and material resources.","Gac Med Mex","Santos, Edgar","Ramirez-Cuapio, Francisco L","Remes-Diaz, Lorena T","Sanchez-Porras, Renan","32412511"],"abstract":["COVID-19 is characterized by acute respiratory distress syndrome progression, which ranges from mild to severe. A percentage of critically ill patients will require endotracheal intubation and mechanical ventilation; therefore, Mexican engineers from different places have had the initiative of creating mechanical ventilators. Although artificial ventilator is one of the last resources for the most severely ill patients, there are patients who are on the verge of not meeting the criteria for intubation; if they are directly intubated, the opportunity for them to overcome the severe phase with high concentration supplemental oxygen would be be missed. Intubation per se induces lung damage, increases the risk of superinfection, and the number of days of ICU stay. Furthermore, non-selective use of artificial ventilators decreases the opportunity for patients who require a ventilator to survive and increases institutional care costs of both human and material resources."],"journal":"Gac Med Mex","authors":["Santos, Edgar","Ramirez-Cuapio, Francisco L","Remes-Diaz, Lorena T","Sanchez-Porras, Renan"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412511","source":"PubMed","week":"202020|May 11 - May 17","locations":["Mexican"],"countries":["Mexico"],"countries_codes":["MEX|Mexico"],"weight":0,"_version_":1666897319209992193,"score":9.490897,"similar":[{"pmid":32481340,"title":"Therapeutic effect of high-flow nasal cannula on severe COVID-19 patients in a makeshift intensive-care unit: A case report.","text":["Therapeutic effect of high-flow nasal cannula on severe COVID-19 patients in a makeshift intensive-care unit: A case report.","INTRODUCTION: Several intensive-care units (ICUs) in Wuhan are nonstandard wards that were repurposed from general wards. Considering the shortage of medical resources and the need to prevent nosocomic infection, the respiratory-treatment strategy in these nonstandard ICUs is different from those in general wards and standard ICUs. High-flow nasal cannula (HFNC) plays an important role in nonstandard ICUs and is beneficial to the patients therein. PATIENT CONCERNS: In this study, we analyzed four cases of HFNC-treated patients with severe coronavirus disease 2019 (COVID-19) in a makeshift ICU and summarized our experience. DIAGNOSES: Four patients diagnosed with COVID-19 according to World Health Organization (WHO) interim guidance were admitted to the makeshift ICU. INTERVENTIONS: All patients had oxygen treatment with HFNC, as well as regular treatment of antivirals and traditional Chinese medicine. OUTCOMES: Two patients survived after treatment, while the other two died from acute respiratory distress syndrome (ARDS) and heart failure, respectively. CONCLUSION: Patients with severe and critical COVID-19 often have poor prognoses after mechanical ventilation, exhibiting corresponding complications such as ventilator-associated pneumonia and deep-vein thrombosis, which significantly prolongs length of stay in the ICU. HFNC could prevent intubation in some patients, thereby avoiding the above complications; however, this needs confirmation in further clinical studies. This treatment reduced difficulty and workloads for healthcare professionals, had good tolerability for patients, might not significantly increase the risk of infection for healthcare professionals, and do not require additional preventive measures against nosocomic infection. HFNC treatment has its advantages in providing oxygen therapy in COVID-19, but healthcare professionals should still pay close attention to changes in patients' oxygenation rates and respiratory frequency.","Medicine (Baltimore)","Lu, Xiao","Xu, Shanxiang","32481340"],"abstract":["INTRODUCTION: Several intensive-care units (ICUs) in Wuhan are nonstandard wards that were repurposed from general wards. Considering the shortage of medical resources and the need to prevent nosocomic infection, the respiratory-treatment strategy in these nonstandard ICUs is different from those in general wards and standard ICUs. High-flow nasal cannula (HFNC) plays an important role in nonstandard ICUs and is beneficial to the patients therein. PATIENT CONCERNS: In this study, we analyzed four cases of HFNC-treated patients with severe coronavirus disease 2019 (COVID-19) in a makeshift ICU and summarized our experience. DIAGNOSES: Four patients diagnosed with COVID-19 according to World Health Organization (WHO) interim guidance were admitted to the makeshift ICU. INTERVENTIONS: All patients had oxygen treatment with HFNC, as well as regular treatment of antivirals and traditional Chinese medicine. OUTCOMES: Two patients survived after treatment, while the other two died from acute respiratory distress syndrome (ARDS) and heart failure, respectively. CONCLUSION: Patients with severe and critical COVID-19 often have poor prognoses after mechanical ventilation, exhibiting corresponding complications such as ventilator-associated pneumonia and deep-vein thrombosis, which significantly prolongs length of stay in the ICU. HFNC could prevent intubation in some patients, thereby avoiding the above complications; however, this needs confirmation in further clinical studies. This treatment reduced difficulty and workloads for healthcare professionals, had good tolerability for patients, might not significantly increase the risk of infection for healthcare professionals, and do not require additional preventive measures against nosocomic infection. HFNC treatment has its advantages in providing oxygen therapy in COVID-19, but healthcare professionals should still pay close attention to changes in patients' oxygenation rates and respiratory frequency."],"journal":"Medicine (Baltimore)","authors":["Lu, Xiao","Xu, Shanxiang"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32481340","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1097/MD.0000000000020393","locations":["Wuhan","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668532114823315457,"score":265.18854},{"pmid":32427774,"title":"Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.","text":["Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.","BACKGROUND: Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome (ARDS) refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS: This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (PaO2<80) despite traditional supportive measures, escalating supplemental oxygen requirements and D-dimer greater than 1.5mug/mL. All patients received protocol directed thrombolytic therapy with Tissue Plasminogen Activator (tPA). RESULTS: All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his P/F ratio improved from 69 to 127. Ventilator support was weaned immediately on post-treatment day 1 and he was extubated on post treatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in PaO2 values overtime. Three of these patients avoided intubation due to COVID-19 associated respiratory failure. CONCLUSIONS: Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy. LEVEL OF EVIDENCE: Level V- Case series of therapeutic effect.","J Trauma Acute Care Surg","Benjamin Christie, D 3rd","Nemec, Hannah M","Scott, Anthony M","Buchanan, John T","Franklin, Christopher M","Ahmed, Aftab","Khan, Muhammad S","Callender, Charles W","James, Erskine A","Christie, Amy B","Ashley, Dennis W","32427774"],"abstract":["BACKGROUND: Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome (ARDS) refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS: This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (PaO2<80) despite traditional supportive measures, escalating supplemental oxygen requirements and D-dimer greater than 1.5mug/mL. All patients received protocol directed thrombolytic therapy with Tissue Plasminogen Activator (tPA). RESULTS: All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his P/F ratio improved from 69 to 127. Ventilator support was weaned immediately on post-treatment day 1 and he was extubated on post treatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in PaO2 values overtime. Three of these patients avoided intubation due to COVID-19 associated respiratory failure. CONCLUSIONS: Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy. LEVEL OF EVIDENCE: Level V- Case series of therapeutic effect."],"journal":"J Trauma Acute Care Surg","authors":["Benjamin Christie, D 3rd","Nemec, Hannah M","Scott, Anthony M","Buchanan, John T","Franklin, Christopher M","Ahmed, Aftab","Khan, Muhammad S","Callender, Charles W","James, Erskine A","Christie, Amy B","Ashley, Dennis W"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427774","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/TA.0000000000002787","topics":["Case Report"],"weight":1,"_version_":1667252837939150848,"score":242.06854},{"pmid":32319424,"title":"Respiratory Support in Novel Coronavirus Disease (COVID-19) Patients, with a Focus on Resource-Limited Settings.","text":["Respiratory Support in Novel Coronavirus Disease (COVID-19) Patients, with a Focus on Resource-Limited Settings.","The ongoing novel coronavirus disease (COVID-19) pandemic is threatening the global human population, including in countries with resource-limited health facilities. Severe bilateral pneumonia is the main feature of severe COVID-19, and adequate ventilatory support is crucial for patient survival. Although our knowledge of the disease is still rapidly increasing, this review summarizes current guidance on the best provision of ventilatory support, with a focus on resource-limited settings. Key messages include that supplemental oxygen is a first essential step for the treatment of severe COVID-19 patients with hypoxemia and should be a primary focus in resource-limited settings where capacity for invasive ventilation is limited. Oxygen delivery can be increased by using a non-rebreathing mask and prone positioning. The presence of only hypoxemia should in general not trigger intubation because hypoxemia is often remarkably well tolerated. Patients with fatigue and at risk for exhaustion, because of respiratory distress, will require invasive ventilation. In these patients, lung protective ventilation is essential. Severe pneumonia in COVID-19 differs in some important aspects from other causes of severe pneumonia or acute respiratory distress syndrome, and limiting the positive end-expiratory pressure level on the ventilator may be important. This ventilation strategy might reduce the currently very high case fatality rate of more than 50% in invasively ventilated COVID-19 patients.","Am J Trop Med Hyg","Dondorp, Arjen M","Hayat, Muhammad","Aryal, Diptesh","Beane, Abi","Schultz, Marcus J","32319424"],"abstract":["The ongoing novel coronavirus disease (COVID-19) pandemic is threatening the global human population, including in countries with resource-limited health facilities. Severe bilateral pneumonia is the main feature of severe COVID-19, and adequate ventilatory support is crucial for patient survival. Although our knowledge of the disease is still rapidly increasing, this review summarizes current guidance on the best provision of ventilatory support, with a focus on resource-limited settings. Key messages include that supplemental oxygen is a first essential step for the treatment of severe COVID-19 patients with hypoxemia and should be a primary focus in resource-limited settings where capacity for invasive ventilation is limited. Oxygen delivery can be increased by using a non-rebreathing mask and prone positioning. The presence of only hypoxemia should in general not trigger intubation because hypoxemia is often remarkably well tolerated. Patients with fatigue and at risk for exhaustion, because of respiratory distress, will require invasive ventilation. In these patients, lung protective ventilation is essential. Severe pneumonia in COVID-19 differs in some important aspects from other causes of severe pneumonia or acute respiratory distress syndrome, and limiting the positive end-expiratory pressure level on the ventilator may be important. This ventilation strategy might reduce the currently very high case fatality rate of more than 50% in invasively ventilated COVID-19 patients."],"journal":"Am J Trop Med Hyg","authors":["Dondorp, Arjen M","Hayat, Muhammad","Aryal, Diptesh","Beane, Abi","Schultz, Marcus J"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319424","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.4269/ajtmh.20-0283","locations":["hypoxemia"],"topics":["Treatment"],"weight":1,"_version_":1666138493654401025,"score":230.82738},{"pmid":32304119,"title":"Tracheostomy during SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society.","text":["Tracheostomy during SARS-CoV-2 pandemic: Recommendations from the New York Head and Neck Society.","The rapid spread of SARS-CoV-2 in 2019 and 2020 has resulted in a worldwide pandemic characterized by severe pulmonary inflammation, effusions, and rapid respiratory compromise. The result of this pandemic is a large and increasing number of patients requiring endotracheal intubation and prolonged ventilator support. The rapid rise in endotracheal intubations coupled with prolonged ventilation requirements will certainly lead to an increase in tracheostomy procedures in the coming weeks and months. Performing tracheostomy in the setting of active SARS-CoV-2, when necessary, poses a unique situation, with unique risks and benefits for both the patient and the health care providers. The New York Head and Neck Society has collaborated on this document to provide guidance on the performance of tracheostomies during the SARS-CoV-2 pandemic.","Head Neck","Miles, Brett A","Schiff, Bradley","Ganly, Ian","Ow, Thomas","Cohen, Erik","Genden, Eric","Culliney, Bruce","Mehrotra, Bhoomi","Savona, Steven","Wong, Richard J","Haigentz, Missak","Caruana, Salvatore","Givi, Babak","Patel, Kepal","Hu, Kenneth","32304119"],"abstract":["The rapid spread of SARS-CoV-2 in 2019 and 2020 has resulted in a worldwide pandemic characterized by severe pulmonary inflammation, effusions, and rapid respiratory compromise. The result of this pandemic is a large and increasing number of patients requiring endotracheal intubation and prolonged ventilator support. The rapid rise in endotracheal intubations coupled with prolonged ventilation requirements will certainly lead to an increase in tracheostomy procedures in the coming weeks and months. Performing tracheostomy in the setting of active SARS-CoV-2, when necessary, poses a unique situation, with unique risks and benefits for both the patient and the health care providers. The New York Head and Neck Society has collaborated on this document to provide guidance on the performance of tracheostomies during the SARS-CoV-2 pandemic."],"journal":"Head Neck","authors":["Miles, Brett A","Schiff, Bradley","Ganly, Ian","Ow, Thomas","Cohen, Erik","Genden, Eric","Culliney, Bruce","Mehrotra, Bhoomi","Savona, Steven","Wong, Richard J","Haigentz, Missak","Caruana, Salvatore","Givi, Babak","Patel, Kepal","Hu, Kenneth"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304119","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hed.26166","keywords":["covid19","sars-cov-2","airway","tracheal stenosis","tracheostomy"],"topics":["Prevention"],"weight":1,"_version_":1666138491122089984,"score":226.44847},{"pmid":32427171,"pmcid":"PMC7228246","title":"Respiratory support for adult patients with COVID-19.","text":["Respiratory support for adult patients with COVID-19.","The COVID-19 pandemic is creating unique strains on the healthcare system. While only a small percentage of patients require mechanical ventilation and ICU care, the enormous size of the populations affected means that these critical resources may become limited. A number of non-invasive options exist to avert mechanical ventilation and ICU admission. This is a clinical review of these options and their applicability in adult COVID-19 patients. Summary recommendations include: (1) Avoid nebulized therapies. Consider metered dose inhaler alternatives. (2) Provide supplemental oxygen following usual treatment principles for hypoxic respiratory failure. Maintain awareness of the aerosol-generating potential of all devices, including nasal cannulas, simple face masks, and venturi masks. Use non-rebreather masks when possible. Be attentive to aerosol generation and the use of personal protective equipment. (3) High flow nasal oxygen is preferred for patients with higher oxygen support requirements. Non-invasive positive pressure ventilation may be associated with higher risk of nosocomial transmission. If used, measures special precautions should be used reduce aerosol formation. (4) Early intubation/mechanical ventilation may be prudent for patients deemed likely to progress to critical illness, multi-organ failure, or acute respiratory distress syndrome (ARDS).","J Am Coll Emerg Physicians Open","Whittle, Jessica S","Pavlov, Ivan","Sacchetti, Alfred D","Atwood, Charles","Rosenberg, Mark S","32427171"],"abstract":["The COVID-19 pandemic is creating unique strains on the healthcare system. While only a small percentage of patients require mechanical ventilation and ICU care, the enormous size of the populations affected means that these critical resources may become limited. A number of non-invasive options exist to avert mechanical ventilation and ICU admission. This is a clinical review of these options and their applicability in adult COVID-19 patients. Summary recommendations include: (1) Avoid nebulized therapies. Consider metered dose inhaler alternatives. (2) Provide supplemental oxygen following usual treatment principles for hypoxic respiratory failure. Maintain awareness of the aerosol-generating potential of all devices, including nasal cannulas, simple face masks, and venturi masks. Use non-rebreather masks when possible. Be attentive to aerosol generation and the use of personal protective equipment. (3) High flow nasal oxygen is preferred for patients with higher oxygen support requirements. Non-invasive positive pressure ventilation may be associated with higher risk of nosocomial transmission. If used, measures special precautions should be used reduce aerosol formation. (4) Early intubation/mechanical ventilation may be prudent for patients deemed likely to progress to critical illness, multi-organ failure, or acute respiratory distress syndrome (ARDS)."],"journal":"J Am Coll Emerg Physicians Open","authors":["Whittle, Jessica S","Pavlov, Ivan","Sacchetti, Alfred D","Atwood, Charles","Rosenberg, Mark S"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427171","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/emp2.12071","keywords":["bipap","covid-19","sars-cov-2","coronavirus","high flow nasal cannula","high flow oxygen","high velocity nasal insufflation","non-invasive ventilation","viral pneumonia"],"topics":["Treatment"],"weight":1,"_version_":1667252837976899584,"score":226.15036}]}